Back to Results
First PageMeta Content
Chronic lower respiratory diseases / Respiratory therapy / Respiratory diseases / Asthma / Chronic obstructive pulmonary disease / Chronic condition / Sanofi / Bronchial hyperresponsiveness / Obstructive lung disease / Firestone Institute for Respiratory Health


ZAI Lab announces a global licensing agreement with Sanofi for two novel compounds in chronic respiratory diseases ShanghaiZAI Lab Limited (ZAI Lab), an innovative biotech company in China, announced today
Add to Reading List

Document Date: 2015-07-30 04:30:57

Open Document

File Size: 359,53 KB

Share Result on Facebook